These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2262 related articles for article (PubMed ID: 28475724)
21. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. van de Schoot L; Romme EA; van der Sangen MJ; Creemers GJ; van Lijnschoten G; van Driel OJ; Rutten HJ; Nieuwenhuijzen GA Ann Surg Oncol; 2008 Jan; 15(1):88-95. PubMed ID: 17896144 [TBL] [Abstract][Full Text] [Related]
22. Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Münch S; Pigorsch SU; Feith M; Slotta-Huspenina J; Weichert W; Friess H; Combs SE; Habermehl D Radiat Oncol; 2017 Nov; 12(1):182. PubMed ID: 29157271 [TBL] [Abstract][Full Text] [Related]
23. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer? Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848 [TBL] [Abstract][Full Text] [Related]
24. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction]. Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322 [TBL] [Abstract][Full Text] [Related]
25. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Kelsey CR; Chino JP; Willett CG; Clough RW; Hurwitz HI; Morse MA; Bendell JC; D'Amico TA; Czito BG Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):770-6. PubMed ID: 17889266 [TBL] [Abstract][Full Text] [Related]
26. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552 [TBL] [Abstract][Full Text] [Related]
27. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467 [TBL] [Abstract][Full Text] [Related]
28. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival. Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212 [TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683 [TBL] [Abstract][Full Text] [Related]
31. Chemoradiation for esophageal cancer: institutional experience with three different regimens. Courrech Staal EF; Aleman BM; van Velthuysen ML; Cats A; Boot H; Jansen EP; van Coevorden F; van Sandick JW Am J Clin Oncol; 2011 Aug; 34(4):343-9. PubMed ID: 20562589 [TBL] [Abstract][Full Text] [Related]
32. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer. Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837 [TBL] [Abstract][Full Text] [Related]
33. Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. Huang TC; Hsu CH; Lin CC; Tu YK Jpn J Clin Oncol; 2015 Nov; 45(11):1023-8. PubMed ID: 26246479 [TBL] [Abstract][Full Text] [Related]
34. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546 [TBL] [Abstract][Full Text] [Related]
35. Survival Benefit of Induction Chemotherapy with Paclitaxel and Carboplatin Followed by Chemoradiation Versus Postoperative Treatment in Locally Advanced Gastric Cancer: A Retrospective Cohort Study. Azadeh P; Gholizadeh Pasha S; Yaghobi Joybari A; Abiar Z; Alahyari S; Taghizadeh-Hesary F J Gastrointest Cancer; 2024 Mar; 55(1):457-466. PubMed ID: 38010493 [TBL] [Abstract][Full Text] [Related]
36. A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin-paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study. Gürler F; Tay F; Sucuoğlu İşleyen Z; Yerlikaya T; Hendem E; Esen SA; Sütçüoğlu O; Işık D; Niğdelioğlu B; Özen M; Şahin E; Şakalar T; Şengül Samancı N; Alan Ö; Hacıbekiroğlu İ; Algın E; Yılmaz MK; Türk HM; Öksüzoğlu B; Yavuz A; Yüksel O; Bora H; Yazıcı O; Özet A; Özdemir N Cancer Med; 2024 Jul; 13(14):e70002. PubMed ID: 39030808 [TBL] [Abstract][Full Text] [Related]
37. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Kleinberg L; Knisely JP; Heitmiller R; Zahurak M; Salem R; Burtness B; Heath EI; Forastiere AA Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):328-34. PubMed ID: 12738305 [TBL] [Abstract][Full Text] [Related]
38. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma. Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597 [TBL] [Abstract][Full Text] [Related]
39. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]